Kalaris Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Berkeley Heights, NJ
KLRS chart
What traders are saying about $KLRS
Latest postsKalaris Therapeutics, Inc. news
- Kalaris Therapeutics, Inc. Estimates – NASDAQ:KLRS
TradingView ·
- Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Yahoo Finance ·
- Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
Yahoo Finance ·
- Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
Yahoo Finance ·
- Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Yahoo Finance ·
- Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board
Yahoo Finance ·
- Kalaris Appoints Laurie Keating to Board of Directors
Yahoo Finance ·
- Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
Yahoo Finance ·
- Kalaris to Present at Clinical Trials at the Summit 2026
Yahoo Finance ·
- Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
Yahoo Finance ·
- Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
Yahoo Finance ·
- Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
Yahoo Finance ·
Kalaris Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Net income | -$43.4M | -$69.2M | -$190.4M | -$168.7M |
| Diluted EPS | $-2.85 | $-51.77 | $-42.09 | $-2.20 |
| Total assets (year end) | $121.7M | $6.2M | $190.8M | $277.1M |
| Cash and equivalents (year end) | $98.1M | $1.6M | $90.1M | $106.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Kalaris Therapeutics, Inc.
- Ticker
- KLRS (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Berkeley Heights, NJ
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1754068
- Former names
- Allovir, Inc., ViraCyte, Inc.
Frequently asked questions
What exchange is Kalaris Therapeutics, Inc. listed on?
Kalaris Therapeutics, Inc. trades on the Nasdaq under the ticker symbol KLRS.
What industry is Kalaris Therapeutics, Inc. in?
Kalaris Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Kalaris Therapeutics, Inc. headquartered?
Kalaris Therapeutics, Inc.'s business address on file with the SEC is in Berkeley Heights, NJ.
When does Kalaris Therapeutics, Inc.'s fiscal year end?
Kalaris Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Kalaris Therapeutics, Inc. report?
Kalaris Therapeutics, Inc. reported $165,000 in revenue for calendar year 2019, according to its SEC filings.